Clinical Trial Update: Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment [Phase 3]

View source ↗

Summary

Phase 3 trial of AM-111 for acute idiopathic sudden sensorineural hearing loss was terminated; results were posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hearing Loss
• Idiopathic Sudden Sensorineural Hearing Loss

Drugs mentioned

• AM-111

Snippet

Sponsor: Auris Medical, Inc. | Conditions: Hearing Loss, Idiopathic Sudden Sensorineural | Phase 3 | Status: TERMINATED | Results posted: 2020-08-07